GAMP 5 publication + copyright + regulatory coordination + status. PUBLICATION: ISPE GAMP 5 Guide 2nd Edition published July 2022 (supersedes 2008 1st Edition); accompanied by APPENDIX series + Companion Guides + Specialist Interest Group publications (ISPE GAMP Records and Data Integrity Guide RDIG + ISPE GAMP Operation of GxP Computerised Systems + ISPE GAMP IT Infrastructure Control and Compliance + others); the Guides are COPYRIGHTED publications + commercially licensed via ISPE bookstore. AUTHORSHIP: ISPE GAMP COMMUNITY OF PRACTICE - hundreds of pharma + biotech + medical device industry professionals + regulators + supplier representatives; chaired + edited + coordinated through ISPE. GxP REGULATORY COORDINATION: GAMP 5 is recognised as industry-standard guidance by FDA + EMA + MHRA + PMDA + Health Canada + Brazilian ANVISA + China NMPA + Singapore HSA + Australia TGA + others; inspectorate expectations align with GAMP 5 + Part 11 + Annex 11; NOT a regulatory mandate but de-facto compliance baseline. 2024-2025 UPDATES + ROADMAP: (a) AI/ML pharma + biotech use cases + 2024 ISPE AI/ML in GxP whitepaper; (b) Cloud + SaaS sector-specific guidance; (c) Computer Software Assurance (CSA) FDA Final Guidance (anticipated 2025-2026) + GAMP 5 alignment; (d) Data integrity remote inspection methodologies; (e) Agile + DevOps maturity model. INDUSTRY APPLICATION: pharma + biotech + medical devices + clinical trials + manufacturing + laboratory + R&D systems; from bench instruments to enterprise ERP/MES/LIMS. ENGAGEMENT: organizations should purchase ISPE GAMP licensed copies + ISPE GAMP Community engagement + sector-specific Specialist Interest Group participation.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.